Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03703050
Title	Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2) (NIVO-ALCL)
Acronym	NIVO-ALCL
Recruitment	Recruiting
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	Gustave Roussy, Cancer Campus, Grand Paris
Indications	anaplastic large cell lymphoma
Therapies	Nivolumab
Age Groups:	adult \| child \| senior
Covered Countries	NLD \| FRA \| DNK